SAN FRANCISCO—Slightly more than half of patients with refractory idiopathic detrusor overactivity (IDO) incontinence have complete restoration of continence one month after intradetrusor injections ...

Injection of botulinum toxin type A into the detrusor smooth muscle is a minimally invasive treatment for incontinence related to neurogenic detrusor overactivity; re-injection is usually necessary ...

In a study, only 39% of patients with overactive bladder continued BTX therapy for more than 5 years. Approximately 60% of patients with overactive bladder (OAB) discontinue onabotulinumtoxinA (BTX) ...

The approval is supported by data from a phase 3 study that assessed the efficacy and safety of Botox in patients aged 5 to 17 years with urinary incontinence due to NDO and using clean intermittent ...

NORTH CHICAGO, Ill., Feb. 10, 2021 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) has approved BOTOX® for the treatment of ...

Background A 49-year old man initially underwent clam ileocystoplasty 14 years ago. A revision of this original procedure was required 11 years ago for intractable detrusor overactivity secondary to ...

-- BOTOX® has demonstrated efficacy and has an established safety profile with over 10 years of clinical use in adult upper limb spasticity NORTH CHICAGO, Ill., July 29, 2021 /PRNewswire/ -- Allergan, ...